Kroger Specialty Infusion is proud to announce it is now dispensing Cuvitru, a subcutaneous treatment for patients with primary immunodeficiency (PI) in people 2 years and older.
Primary immunodeficiency diseases (PI) are a group of more than 400 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some affect a single part of the immune system; others may affect one or more components of the system.
While the diseases may differ, they all share one common feature: each result from a defect in one of the functions of the body's normal immune system. Because one of the most important functions of the normal immune system is to protect us against infection, patients with PI commonly have an increased susceptibility to infection.
CUVITRU [Immune Globulin Subcutaneous (Human)] 20% provides reliable infection protection and consistent Ig levels, which helps the body fight infections due to PI. Cuvitru is made from human plasma donated by healthy people. This replaces antibodies that are not working properly or are missing from the body to help the body protect against infection.
Ryan McGrath, Vice President of Sales for Kroger Specialty Infusion, shared his excitement on the news of dispensing Cuvitru. "Kroger Specialty Infusion is proud to serve, and support, the PI community. Our ability to provide a full portfolio of branded options for each patient is a differentiator in today's marketplace. Being selected to offer Cuvitru celebrates an enhancement of Kroger Health's commitment to the mission of helping people live healthier lives."
In every instance at Kroger Specialty Infusion, you can expect dedicated Ig clinical teams, access to limited distribution medications, simple patient enrollment, experts in complex insurance management, comprehensive financial services, and personalized patient care support.
About Kroger Specialty Infusion:
Kroger Specialty Infusion is a specialized home infusion provider for Subcutaneous Immune Globulin (SCIG) and IV Immune Globulin (Ig) for autoimmune and primary immune deficiency diseases. We provide an individualized care plan to ensure each patient achieves an optimal treatment outcome within a safe environment in their home, our infusion suite, and the physicians' office. Our focused approach to disease management, along with our expertise in complex illnesses, allows us to offer a range of therapeutic medications and treatments. We are also a leading provider of plasma therapies. For more information, visit www.krogerspecialtyinfusion.com.
About Kroger Specialty Pharmacy:
At Kroger Specialty Pharmacy, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As one of the nation's leading specialty pharmacies, Kroger Specialty Pharmacy offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Cystic Fibrosis, Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, HAE plus others. Kroger Specialty Pharmacy services patients in all 50 states and Puerto Rico and is ACHC and URAC Accredited in numerous sites. Kroger Specialty Pharmacy's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.krogerspecialtypharmacy.com.
About Takeda Pharmaceuticals:
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan. For more information, visit www.takeda.com or learn more about Cuvitru at www.cuvitru.com.